Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Home Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

/ Publications

Share the Post

About the Author

Related Posts

Read More
Behzad Aghazadeh, PhD
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With nab-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
AADi Announces Licensing Agreement with Celgene for Nanotechnology-Based Drug Candidate

Comments

Comments are closed.